REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · IEX Real-Time Price · USD
15.90
+0.26 (1.66%)
Apr 23, 2024, 4:00 PM EDT - Market closed
REGENXBIO Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for REGENXBIO stock have an average target of 40.56, with a low estimate of 21 and a high estimate of 55. The average target predicts an increase of 155.09% from the current stock price of 15.90.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for REGENXBIO stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 2 | 2 | 2 | 3 | 6 | 6 |
| Hold | 3 | 3 | 3 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $40 | Strong Buy | Maintains | $40 | +151.57% | Apr 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +126.42% | Mar 11, 2024 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $20 → $35 | Hold → Buy | Upgrades | $20 → $35 | +120.13% | Mar 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $52 | Strong Buy | Maintains | $52 | +227.04% | Mar 7, 2024 |
| Barclays | Barclays | Buy Maintains $45 → $55 | Buy | Maintains | $45 → $55 | +245.91% | Mar 7, 2024 |
Financial Forecast
Revenue This Year
136.28M
from 90.24M
Increased by 51.02%
Revenue Next Year
239.39M
from 136.28M
Increased by 75.66%
EPS This Year
-4.62
from -6.02
EPS Next Year
-2.23
from -4.62
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 299.0M | 434.7M | 518.7M | 488.3M | 598.6M |
| Avg | 136.3M | 239.4M | 304.2M | 411.7M | 494.2M |
| Low | 78.4M | 78.4M | 197.5M | 263.4M | 334.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 231.3% | 219.0% | 116.7% | 60.5% | 45.4% |
| Avg | 51.0% | 75.7% | 27.1% | 35.3% | 20.0% |
| Low | -13.1% | -42.5% | -17.5% | -13.4% | -18.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.48 | 1.52 | 2.42 | 0.13 | 3.28 |
| Avg | -4.62 | -2.23 | -1.44 | -0.71 | 0.26 |
| Low | -5.55 | -5.05 | -3.83 | -1.79 | -3.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.